Premium
The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP ‐ BFM ALL protocols
Author(s) -
Paganin Maddalena,
Grillo Maria Francesca,
Silvestri Daniela,
Scapinello Greta,
Buldini Barbara,
Cazzaniga Giovanni,
Biondi Andrea,
Valsecchi Maria Grazia,
Conter Valentino,
Kronnie Geertruij,
Basso Giuseppe
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15449
Subject(s) - pten , medicine , cancer research , oncology , mutation , suppressor , adverse effect , tumor suppressor gene , gene , cancer , biology , pi3k/akt/mtor pathway , genetics , carcinogenesis , signal transduction
Summary Notwithstanding the improvement in treatment results for paediatric T cell acute lymphoblastic leukaemia (T‐ ALL ) it remains important to understand if genetic aberrations influence therapy response. PTEN tumour suppressor gene inactivation is a frequent event in T‐ ALL but its effect on patient therapy response is debatable. We analysed the effect of the presence of mutated PTEN on outcome in 257 children with T‐ ALL treated with Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)‐Berlin‐Frankfürt‐Münster (BFM) protocols. PTEN mutations were present in 31 (12·1%) patients and were significantly associated with increased risk of relapse. PTEN mutations also indicate a poor prognosis in T‐ ALL patients in the absence of NOTCH 1 mutations or in the group of patients with co‐presence of PTEN mutation and deletions. These results indicate that PTEN genomic aberrations and the biologically consequential PTEN inactivation contribute to adverse therapy response in T‐ ALL patients; PTEN status as a biomarker may contribute to the development of new molecularly‐defined stratification algorithms.